- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00090779
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
연구 개요
상세 설명
Combination antiretroviral therapy has resulted in significantly decreased morbidity and mortality, incidence of opportunistic infections, and hospitalizations in HIV infected people. However, because of long-term toxicities associated with long-term use of antiretrovirals and the persistence of virus in latent reservoirs, it is unclear when it is best to initiate therapy in recently infected individuals. This study compared the virologic outcomes of adults recently infected with HIV who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), coformulated as Truvada, and lopinavir/ritonavir (LPV/RTV), coformulated as Kaletra [immediate treatment (IT arm)], with those who received no treatment [deferred treatment (DT arm)].
The original study lasted 96 weeks. Participants were randomly assigned to one of two groups (IT arm vs. DT arm). For the first 36 weeks of the study, IT arm participants received FTC/TDF once daily and LPV/RTV twice daily. Some IT arm participants received a different ART regimen as determined by the participant and study staff, if appropriate. DT arm participants received no treatment for the duration of the study. At Week 37, participants from both arms were offered treatment continuation or initiation until Week 96 if they had a high viral load, low CD4 count, or experienced HIV-related symptoms (Step 2). Study visits occurred at screening, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 37, 38, 40, and every 4 weeks thereafter. Clinical assessment and blood collection occurred at all visits. Urine tests occurred at selected visits. Participants were asked to complete an adherence questionnaire at Weeks 12, 24, and 36.
Per the recommendations the DSMB review in June 2009, this protocol was terminated as originally written with the exception of those participants in the IT arm in the middle of the first 36 weeks of treatment. Those participants were to continue on treatment until the end of the 36 weeks. At that point treatment decisions were made on best practice guidelines. In addition, the study duration was extended to include a 5 year follow up of participants who did not initiate long-term antiretroviral therapy (Step 3).
The study was reviewed by an SMC on December 8, 2010. The SMC recommended the study close to long term follow-up because only very few participants enrolled in this portion of the study.
All the results except for the CD4 analysis and time to treatment initiation and deaths were based on the database frozen on July 2, 2009. The results for the CD4 analysis and time to treatment initiation and deaths were based on the database frozen on January 30, 2012.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
San Diego, California, 미국, 92103
- Ucsd, Avrc Crs (701)
-
San Francisco, California, 미국, 94110
- Ucsf Aids Crs (801)
-
Torrance, California, 미국, 90502
- Harbor-UCLA Med. Ctr. CRS (603)
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado Hospital CRS (6101)
-
-
Florida
-
Miami, Florida, 미국, 33139
- University of Miami AIDS CRS (901)
-
-
Georgia
-
Atlanta, Georgia, 미국, 30308
- The Ponce de Leon Center CRS
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern University CRS (2701)
-
Chicago, Illinois, 미국, 60612
- Rush Univ. Med. Ctr. ACTG CRS (2702)
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202-5250
- Indiana University Hospital (2601)
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- IHV Baltimore Treatment CRS (4651)
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital ACTG CRS (101)
-
Boston, Massachusetts, 미국, 02115
- Brigham and Women's Hosp. ACTG CRS (107)
-
-
Missouri
-
Saint Louis, Missouri, 미국, 63110
- Washington University CRS (2101)
-
-
New York
-
New York, New York, 미국, 10003
- Beth Israel Medical Center
-
New York, New York, 미국, 10032
- HIV Prevention & Treatment CRS (30329)
-
Rochester, New York, 미국, 14642
- AIDS Care CRS (1108)
-
Rochester, New York, 미국, 14642
- University of Rochester ACTG CRS (1101)
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27516
- Unc Aids Crs (3201)
-
Greensboro, North Carolina, 미국, 27401
- Moses H. Cone Memorial Hospital CRS (3203)
-
Greensboro, North Carolina, 미국, 27401
- Regional Center for Infectious Disease, Wendover Medical Center CRS (3203)
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- The Ohio State Univ. AIDS CRS (2301)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Hosp. of the Univ. of Pennsylvania CRS (6201)
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02906
- The Miriam Hosp. ACTG CRS (2951)
-
-
Washington
-
Seattle, Washington, 미국, 98104
- University of Washington AIDS CRS (1401)
-
Seattle, Washington, 미국, 98104
- UW Primary Infection Clinic CRS (1404)
-
-
-
-
-
Lima, 페루, 18 PE
- Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301)
-
-
Lima
-
San Miguel, Lima, 페루
- San Miguel CRS
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria for Step 1:
- Recently infected with HIV
- No prior antiretroviral therapy (ART)
- CD4 count of 350 cells/mm3 or more AND a CD4% of 14% or more within 21 days prior to study entry
- HIV viral load of 500 copies/ml or more within 21 days prior to study entry
- Required laboratory values obtained within 21 days prior to study entry
- 18 years or older
- Ability and willingness to provide written informed consent
- Willing to use acceptable forms of contraception
Exclusion Criteria for Step 1:
- HIV progression to CDC category B or C disease
- Pregnancy or breastfeeding
- History of pancreatitis or coronary artery disease
- Prior ART. Participants who took antiretrovirals for postexposure prophylaxis more than one year prior to study entry are not excluded.
- Certain medications within 21 days prior to study entry. Participants who agree to receive an alternative ART regimen approved by the investigator will not be excluded.
- Previously received an investigational anti-HIV vaccine
- Current therapy with systemic corticosteroids. Patients who are taking a short course (less than 21 days) of corticosteroids are not excluded.
- Current therapy with systemic chemotherapeutic agents; nephrotoxic systemic agents; immunomodulatory treatments, including interleukin-2; or investigational agents
- Known allergy or sensitivity to study drugs or their formulations
- Current alcohol or drug use that, in the opinion of the investigator, would interfere with the study
- Serious medical or psychiatric illness that, in the opinion of the investigator, would interfere with the study
- Hepatitis B surface antigen positive within 21 days prior to study entry
- Known resistance to one or more components of the study drug regimen
Inclusion Criteria for Step 2:
subjects in DT arm who meet one of the following five criteria will be advised to enter step 2 and initiate ART:
- CD4 cell counts below 350 cells/mm3 on 2 consecutive determinations at least 4 weeks apart at or after the step 1, week 12 study visit
- HIV-1 RNA above 750,000 copies/mL confirmed on 2 consecutive determinations at least 1 week apart at or after the step 1, week 4 study visit
- HIV-1 RNA above 200,000 copies/mL on 2 consecutive determinations at least 1 week apart at or after the step 1, week 12 study visit
- Clinical progression to CDC category B or C disease
- CD4 count below 200 cells/mm3 or CD4 percent less than 14% at any time on study
subjects in IT arm who meet one of the following five criteria after discontinuing study medications will be advised to enter step 2 and re-initiate ART:
- CD4 cell counts below 350 cells/mm3 on 2 consecutive determinations at least 4 weeks apart at or after the step 1, week 12 post-treatment- discontinuation study visit
- HIV-1 RNA above 750,000 copies/mL confirmed on 2 consecutive determinations at least 1 week apart at or after the step 1, week 4 post-treatment- discontinuation study visit
- HIV-1 RNA above 200,000 copies/mL on 2 consecutive determinations at least 1 week apart at or after the step 1, week 12 post-treatment- discontinuation study visit
- Clinical progression to CDC category B or C disease
CD4 count below 200 cells/mm3 or CD4 percent less than 14% at any time on study
Exclusion Criteria for Step 2:
- Pregnancy or breastfeeding
Inclusion Criteria for Step 3:
- Study participants who were on Step 1, IT arm and had completed or ended prematurely the 36 week course of early ART and did not on ART either because they did not meet eligibility criteria for Step 2 or because they did not start ART even after meeting the Step 2 eligibility criteria.
- Study participants on Step 1, DT arm who were not on ART either because they did not meet eligibility criteria for Step 2 or because they did not start ART even after meeting the Step 2 eligibility criteria.
- Previous A5217 participants who had either completed the study or ended prematurely their participation in the study, AND were not on ART either because they never met eligibility criteria for Step 2 or because they had not started ART even after meeting the Step 2 eligibility criteria.
- All A5217 participants who were on Step 1 and in the midst of their 36 weeks of randomized ART and who completed a portion or all of the 36 weeks of originally recommended therapy, AND chose then to interrupt their ART.
Exclusion Criteria for Step 3:
- Participants who were on Step 1, IT arm of the study receiving ART.
- Participants in Step 2 or who had otherwise initiated long-term ART, regardless of whether they were on treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: IT arm
IT (immediate treatment) arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily
|
once daily
twice daily
|
간섭 없음: DT arm
DT (deferred treatment) arm participants received no treatment
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Ranked Log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at 72 and 76 Weeks for the IT Arm and DT Arm
기간: At Weeks 72 and 76
|
The primary endpoint is (i) the average of log10 viral loads (VL) at wks 72 and 76 for participants who continued to wk 72 off ARV for the DT arm, (ii) average wk 72 and 76 VL for those who continued to wk 36 off ARV for the IT arm and (iii) an assigned VL rank for the "failures" who needed ARVs or met criteria for entry into Step 2 prior to these study visits.
The assigned rank for the failures was either the last observed rank carried forward or the worst rank relative to the other possible outcomes.
This approach was designed to, if anything, bias against finding a treatment effect.
To illustrate, consider five participants who enter the study (A, B, C, D, and E), 4 of whom (A, B, C, D) make it to 72 wks off therapy with RNA levels that increase from A to D. Participant E enters Step 2 at wk 12, at which time his RNA is in the 50th percentile.
This rank would be carried forward, so the rank order of the log10 HIV-1 RNA endpoints would be A B E C D.
|
At Weeks 72 and 76
|
Ranked log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at Weeks 72 and 76 for the IT Arm and Ranked log10 HIV-1 RNA Viral Load (log10 Copies/mL) Averaged at Weeks 36 and 40 for the DT Arm
기간: IT arm (weeks 72 and 76) and DT arm ( weeks 36 and 40)
|
The primary endpoint is (i) average wk 36 and 40 VL for those who continued to wk 36 off ARV for the DT arm, (ii) average wk 72 and 76 VL for those who continued to wk 36 off ARV for the IT arm and (iii) an assigned VL rank for the "failures" who needed ARVs or met criteria for entry into Step 2 prior to these study visits.
The assigned rank for the failures was either the last observed rank carried forward or the worst rank relative to the other possible outcomes.
This approach was designed to, if anything, bias against finding a treatment effect.
To illustrate, consider five participants who enter the study (A, B, C, D, and E), 4 of whom (A, B, C, D) make it to 72 wks off therapy with RNA levels that increase from A to D. Participant E enters Step 2 at wk 12, at which time his RNA is in the 50th percentile.
This rank would be carried forward, so the rank order of the log10 HIV-1 RNA endpoints would be A B E C D.
|
IT arm (weeks 72 and 76) and DT arm ( weeks 36 and 40)
|
Number of Participants Experiencing Either a CDC Category B or C Diagnosis, CD4<200 Cells/mm^3 or CD4 Percent <14%.
기간: 96 weeks since randomization
|
96 weeks since randomization
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in CD4 Counts Cells/mm^3 From Week 36 for IT Arm and From Week 0 for DT Arm
기간: IT arm (weeks 36, 60, 72, 84 and 96) and DT arm (weeks 0, 24, 36, 48 and 60)
|
IT arm (weeks 36, 60, 72, 84 and 96) and DT arm (weeks 0, 24, 36, 48 and 60)
|
|
Number of Participants Meeting Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
기간: 96 weeks since randomization
|
The clinical, virologic, or immunologic criteria for treatment initiation or re-initiation include CD4 count below 350 cells/mm^3 on two consecutive determinations at least 4 weeks apart, at least 12 weeks into the study or 12 weeks post-treatment discontinuation, (2) confirmed CD4 count below 200 cells/mm^3 or CD4 percent below 14% at any time on study, (3) confirmed HIV-1 RNA level above 750,000 copies/mL 4 weeks into the study or above 200,000 copies/mL 12 weeks or more into the study, or (4) CDC Category B or C diagnosis.
|
96 weeks since randomization
|
Number of Participants in IT Arm Off Treatment Before 36 Weeks
기간: At Week 36
|
The study provided fixed-dose combination emtricitabine/tenofovir DF 200/300 mg orally once daily and lopinavir/ritonavir 200/50 mg administered either as two tablets twice daily or four tablets once daily, for the first 36 weeks for individuals in the IT arm.
|
At Week 36
|
Time to Meeting the Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
기간: 96 weeks since randomization
|
5th, 10th, 25th, 50th, 75th and 90th percentiles in weeks from randomization to meeting the criteria for treatment initiation or re-initiation which include CD4 count below 350 cells/mm^3 on two consecutive measurements at least 4 weeks apart, at least 12 weeks into the study or 12 weeks post-treatment discontinuation, confirmed CD4 count below 200 cells/mm^3 or CD4 percent below 14% at any time on study, confirmed HIV-1 RNA level above 750,000 copies/mL 4 weeks into the study or above 200,000 copies/mL 12 weeks or more into the study, or CDC Category B or C diagnosis.
|
96 weeks since randomization
|
Time From Study Entry in DT Arm Participants or From Week 36 in IT Arm Participants to Meeting the Clinical, Virologic, or Immunologic Criteria for Treatment Initiation or Re-initiation
기간: 96 weeks since randomization
|
5th, 10th, 25th, 50th, 75th and 90th percentiles in weeks from randomization for DT arm or from week 36 for IT arm to meeting the criteria for treatment initiation or re-initiation which include two consecutive CD4 count below 350 cells/mm^3 at least 4 weeks apart, at least 12 weeks into the study or 12 weeks post-treatment discontinuation, confirmed CD4 count below 200 cells/mm^3 or CD4 percent below 14% at any time on study, confirmed HIV-1 RNA level above 750,000 copies/mL 4 weeks into the study or above 200,000 copies/mL 12 weeks or more into the study, or CDC Category B or C diagnosis.
|
96 weeks since randomization
|
Time to Treatment Initiation or Death
기간: 5 years since randomization
|
5th, 10th, 25th, 50th and 75th percentiles in weeks from randomization to treatment initiation or death
|
5 years since randomization
|
공동 작업자 및 조사자
수사관
- 연구 의자: Christine Hogan, MD, Division of Infectious Diseases, Columbia University College of Physicians and Surgeons
간행물 및 유용한 링크
일반 간행물
- Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, Zhang HT, Price D, Phillips R, Weber J. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS. 2002 Oct 18;16(15):2049-54. doi: 10.1097/00002030-200210180-00010.
- Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis. 2004 May 15;38(10):1447-53. doi: 10.1086/420745. Epub 2004 Apr 30.
- Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002 Aug 8;347(6):385-94. doi: 10.1056/NEJMoa013552.
- Pilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest. 2004 Apr;113(7):937-45. doi: 10.1172/JCI21540. Erratum In: J Clin Invest. 2006 Dec;116(12):3292.
- Messer K, Vaida F, Hogan C. Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217. Contemp Clin Trials. 2006 Dec;27(6):506-17. doi: 10.1016/j.cct.2006.07.003. Epub 2006 Jul 25.
- Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S; A5217 Study Team. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012 Jan 1;205(1):87-96. doi: 10.1093/infdis/jir699. Epub 2011 Dec 15.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ACTG A5217
- 1U01AI068636 (미국 NIH 보조금/계약)
- AIEDRP AIN503
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
CDC FoundationGilead Sciences알려지지 않은
-
University of WashingtonNational Institute of Mental Health (NIMH)모병
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
-
Erasmus Medical Center모집하지 않고 적극적으로
Emtricitabine/ tenofovir disoproxil fumarate에 대한 임상 시험
-
Children's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Gilead Sciences 그리고 다른 협력자들아직 모집하지 않음
-
University of WashingtonGilead Sciences; CONRAD완전한
-
Marla KellerNational Institute of Allergy and Infectious Diseases (NIAID)종료됨
-
Hospitales Universitarios Virgen del RocíoInstituto de Biomedicina de Sevilla초대로 등록간염, 바이러스, 인간 | HIV 감염 기본 | HIV 및 간염을 제외한 성병스페인
-
University Hospital, CaenMerck Sharp & Dohme LLC아직 모집하지 않음
-
Instituto de Investigación Hospital Universitario...완전한
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.모병
-
New Discovery LLC모병